Recornea

Market position

Recornea describes itself as a clinical-stage ophthalmic medtech company and its GROSSO® Reshaper as the world's first nitinol intracorneal implant for keratoconus. Company materials frame existing options - corrective laser surgery, transplantation, micro-prosthetic implants, contact lenses and spectacles - as inadequate or unpredictable. Market sizing statements differ across sources: a EuroQuity profile cites 175 million people affected worldwide, while an earlier Gust profile cited roughly 15 million people and a $9B market.

Use of nitinol shape-memory alloy to produce an intracorneal implant with a pre-defined physiological curvature that reshapes the whole cornea, positioned as more predictable and less invasive than corneal transplantation or existing corneal implants; supporting elements include patents and trade secrets, ISO 13485:2016 certification, and preclinical efficacy and durability data.

Technology

The core technology couples minimally invasive surgery with biocompatible, bio-enhanced devices made from nitinol, a super-elastic shape-memory alloy with an established history in medical devices. The GROSSO® Reshaper is a patented intra-corneal implant with a pre-defined curvature mimicking a healthy cornea, inserted into a circular corneal pocket to mechanically reshape the cornea. Company materials cite preclinical rabbit data showing corneal flattening (K1 reduction of 7D; K2 and Kave reduction of 5-6D, with follow-up to six months), flexibility and durability testing in explanted pig eyes and human corneas, and biocompatibility findings. A separate grant-funded project, NiTi4EYE, covers development of an injector to standardise the implantation procedure. A glaucoma filtering device is also under development on the same materials platform.

Go-to-market

Clinical validation through investigator sites in Europe (IMO Grupo Miranza in Barcelona, Spain; an additional Italian site authorised by the Comitato Etico Territoriale Lazio Area 3 and the Italian Ministry of Health), collaboration with key opinion leaders such as Dr José Luis Güell (principal investigator) and Dr Pierre Fournié (University Hospital of Toulouse), participation in the EU-funded HUMANeye project coordinated by the IMO Foundation, and presentation at ESCRS congresses. Commercially the company indicates B2B sales to hospitals and distribution partnerships.

Patients with keratoconus, specifically stages 2, 3 and 4, and the ophthalmic surgeons and hospitals that would implant the device; a pipeline glaucoma device would target glaucoma patients.

Geography

Founded and originally incorporated in Singapore; headquarters relocated to Trieste, Italy in 2020, with a new Trieste office in 2025 and a registered address at Via della Ginnastica 9, 34125 Trieste. Clinical activity is in Spain (IMO Barcelona) and Italy, with project collaborators in France (University Hospital of Toulouse).

History

Key milestones reported by the company: foundation in Singapore (2019); relocation to Italy with HQ in Trieste (2020); closing of a pre-seed investment from Entrepreneur First Singapore, Entrepreneur First UK, GFactor and Health Wildcatters (2021); in 2023, completion of an in vitro preclinical study, ISO 13485:2016 certification of its quality management system as legal manufacturer of the GROSSO® Reshaper, first public presentation of the device at the ESCRS congress, and an ESCRS innovation award at the Innovation Den; in 2024, completion of an in vivo preclinical rabbit study and the start of the First-In-Human clinical trial in keratoconus patients; in 2025, closing of a seed investment and a new office in Trieste. A EuroQuity profile records a Site Initiation Visit at IMO Barcelona on 23 April 2024 ahead of first-subject enrolment.

Risks & controversies

The lead product remains an investigational device not approved for sale, with clinical evidence limited to a small First-In-Human cohort and preclinical animal data. Public sources are inconsistent on basic facts: headcount is given as 2 (Gust), 3-5 (EuroQuity) and 201-500 (startupintros); founding/creation dates and cumulative funding figures also differ across sources (€4.4M non-dilutive plus €1.4M dilutive per the company site, €2.6M per EuroQuity, $1.6M per startupintros). One EuroQuity note indicates the €1.2M seed round was still €450k short with a 31 December 2024 deadline. Some third-party profile content appears partly auto-generated and includes statements such as a planned pivotal trial and CE market entry that are not corroborated by primary company sources.